Prescribing biosimilars

BMJ. 2018 Jul 24:362:k3141. doi: 10.1136/bmj.k3141.

Authors

Jeffrey K Aronson^{1

2}, Ben Goldacre³, Robin E Ferner^{2

4}

Affiliations

¹ Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, Oxford, UK jeffrey.aronson@phc.ox.ac.uk.
² West Midlands Centre for Adverse Drug Reactions, City Hospital, Birmingham, UK.
³ Centre for Evidence Based Medicine, Nuffield Department of Primary Care Health Sciences, Oxford, UK.
⁴ Institute of Clinical Sciences, University of Birmingham, UK.

PMID: 30042142
DOI: 10.1136/bmj.k3141

No abstract available

Publication types

Editorial

MeSH terms

Biosimilar Pharmaceuticals*
Drug Substitution / statistics & numerical data
Drugs, Generic*
Evidence-Based Practice
Humans
Pharmacovigilance*
Practice Patterns, Physicians' / statistics & numerical data*

Substances

Biosimilar Pharmaceuticals
Drugs, Generic